What is Torigen Pharmaceuticals?
Torigen Pharmaceuticals Inc. is dedicated to the development and delivery of accessible immuno-oncology products for companion animals. The company's proprietary technology leverages a portion of the pet's own tumor to create a personalized cancer vaccine. With a foundation built on over a decade of pre-clinical research and publications, Torigen's team is focused on pioneering advanced veterinary cancer biologics designed to stimulate the animal's immune system to recognize foreign tumor-associated antigens and reverse immune senescence, offering a novel therapeutic avenue for pets battling cancer.
How much funding has Torigen Pharmaceuticals raised?
Torigen Pharmaceuticals has raised a total of $16.1M across 2 funding rounds:
Series A
$3.1M
Series A
$13M
Series A (2019): $3.1M with participation from Connecticut Innovations
Series A (2022): $13M led by Emerald Development Managers, Gaingels, and Connecticut Innovations
Key Investors in Torigen Pharmaceuticals
Connecticut Innovations
Connecticut Innovations (ctinnovations.com) is Connecticuts strategic venture capital arm and quasipublic investment agency, providing equity and debt financing, strategic guidance, and connections to help innovative, growing companies in the state scale, with dedicated funds for sectors like AI/quantum, climate tech, and biosciences.
Emerald Development Managers
Emerald Development Managers is a venture capital firm that invests in exceptional scientific and engineering teams focused on solving real-world problems. They specialize in sectors such as life sciences, enterprise software, cybersecurity, industrial technology, and sustainability.
Gaingels
Gaingels is the leading investment syndicate in support of and representing the LGBTQ community and allies in the venture capital space. They invest in companies with LGBT founders and C-suite leaders at all stages of growth, as well as in other high-growth companies resolved on building more inclusive teams.
What's next for Torigen Pharmaceuticals?
The recent major strategic investment signifies a pivotal moment for Torigen Pharmaceuticals, likely enabling the company to accelerate its product development pipeline, expand its operational capacity, and potentially scale its commercialization efforts. This substantial backing from investors suggests a strong belief in Torigen's unique immuno-oncology platform for companion animals. Future strategic initiatives may include further clinical validation, regulatory approvals, and market penetration to establish Torigen as a leader in veterinary cancer therapeutics. The company's focus on personalized vaccines positions it to address a growing need for advanced and affordable cancer treatments in the veterinary market.
See full Torigen Pharmaceuticals company page
